Latest Breaking News On - Division of leukemia - Page 5 : comparemela.com

City of Hope and TGen Research Reveals What Potentially Causes a Leukemia to Become More Aggressive

City of Hope and TGen Research Reveals What Potentially Causes a Leukemia to Become More Aggressive
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesOrange countyPatrick pirrotteLos angelesGuido marcucciLynda carter altmanJeffrey trentCarter altmanNature communicationsDepartment of hematologic malignancies translational scienceDivision of leukemiaLeukemia researchCarter altman foundationProduct serviceNational cancerTranslational genomics research institute tgen

City of Hope and TGen Research Reveals What Potentially Causes a Leukemia to Become More Aggressive

City of Hope and TGen Research Reveals What Potentially Causes a Leukemia to Become More Aggressive
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesOrange countyLynda carter altmanJeffrey trentPatrick pirrotteLos angelesGuido marcucciLetisia marquezCarter altmanDivision of leukemiaNature communicationsTranslational genomics research instituteCarter altman foundationDepartment of hematologic malignancies translational scienceTranslational genomics research institute tgenNational cancer

Dr Danilov on the Investigation of BTK Degraders in CLL

Alexey Danilov, MD, PhD, discusses the investigation of BTK degraders in the treatment of chronic lymphocytic leukemia.

Alexey danilovDivision of leukemiaToni stephenson lymphoma center professorDepartment of hematology hematopoietic cell transplantationHematopoietic cell transplantationInternational workshop on cllOnclive tv

Primary Endpoint Met for Revumenib in Patients with AML and ALL

In the recent AUGMENT-101 trial, revumenib met the study goals of complete remission in patients with acute myeloid leukemia or acute lymphoid leukemia.

Ibrahim aldossMichaela metzgerDepartment of hematology hematopoietic cell transplantationDivision of leukemiaBreakthrough therapy designationHematopoietic cell transplantationAcute myeloid leukemiaAcute lymphoid leukemia

Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis

– Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an additional 14%.

Michaela metzgerIbrahim aldossSharon klahreDepartment of hematology hematopoietic cell transplantationPharmaceuticals incEuropean commissionData monitoring committeeDivision of leukemiaExchange commissionSyndax pharmaceuticalsSyndax pharmaceuticals incDrug administrationPrnewswire syndax pharmaceuticals nasdaqInternational numberIndependent data monitoring committeeChief executive officer